Y-90 microspheres achieved 98.5% response rate and 100% local tumor control in unresectable HCC patients across multicenter trial.
FDA Approves Radioembolization Therapy for Liver Cancer Read More »
MT-sDNA screening showed 0.2% CRC detection rate and 73% false-positive rate, raising questions about effectiveness in average-risk patients.
The Utility of Multitarget Stool DNA Testing in Community-Based Clinical Practice Read More »
Total neoadjuvant therapy with FLOT may optimize outcomes, but ctDNA could guide personalized treatment decisions.
Making Sense of FLOT, Durvalumab, and the Role of Real-World Tumor Biology Read More »
